p continues to expand Novo Nordisk® Diabetes value market leadership expansion driven by the GLP-1 and insulin franchises GLP-1 value market share has increased by ~3%-points since 2019, driven by: • Ozempic® launched in 48 countries • Uptake of Ozempic® and launch of Rybelsus® in North America Operations Insulin value market share has increased by 0.2%-points since 2019, driven by: • New-generation insulins in International Operations facilitated by our Market Fit approach
Download PDF file